Most Read Articles
3 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 3 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Hypertensive disorders of pregnancy may harm babies’ brain development

20 Oct 2020

Exposure to maternal hypertensive disorders of pregnancy (HDP) appears to hinder neurodevelopment in infants, a study reports.

The study included 4,031 mother–infant pairs (mean maternal age, 26.8 years; mean gestation age of infants, 38.8 weeks; 55.7 percent boys). A total of 362 (9.0 percent) of the mothers had HDP, of which 88 had chronic hypertension, 233 had gestational hypertension, and 41 had pre-eclampsia. More than half of the mothers (54.2 percent) were receiving folic acid supplementation before pregnancy, and 1.8 percent had passive smoking exposure during pregnancy.

Of the infants, 75.5 percent were delivered by C-section. The mean birth weight was 3,300.4 g. At 6 months of age, 500 (12.4 percent) infants showed neurodevelopmental delay according to the Gesell Developmental Schedules.

Maternal chronic hypertension was significantly associated with low development quotient on fine motor (β, −3.32), adaptability (β, −2.87), language (β, −1.23), and social behaviour (β, −2.53). Meanwhile, gestational hypertension had a significant association with low development quotient on social behaviour (β, −1.42).

On logistic regression analysis, maternal chronic hypertension contributed to a higher likelihood of neurodevelopmental delay on fine motor (odds ratio [OR], 1.85, 95 percent confidence interval [CI], 1.19−2.89), adaptability (OR, 2.32, 95 percent CI, 1.42−3.78), language (OR, 2.86, 95 percent CI, 1.74−4.70), and social behaviour (OR, 2.13, 95 percent CI, 1.73−2.59).

The present data highlight the need for greater paediatric surveillance of infants whose mothers had HDP in order to carry out early interventions that may help improve neurodevelopmental outcome.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 3 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.